Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 162 clinical trials
CPX-351+GO in Subjects 55 Years Old, or Older, With AML

-dose cytarabine, or lenalidomide or a clinical trial drug in combination with hypomethylating agents or low-dose cytarabine, but may not have received intensive AML treatment with anthracyclines and/or

ejection fraction
daunorubicin
lenalidomide
anthracyclines
cytarabine/daunorubicin
  • 0 views
  • 29 Dec, 2021
  • 1 location
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

A phase I-II trial based on the combination of three drugs regimen LDAC or Azacitidine + Venetoclax + Quizartinib that in this population could be well tolerated by a sequential type administration. The first objective is to achieve rapid control of the disease, using two different schemes, one based in …

azacitidine
ejection fraction
cytarabine
venetoclax
  • 0 views
  • 25 May, 2021
  • 15 locations
Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases

This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a peripheral blood stem cell transplant

myelopathy
cerebellar degeneration
apheresis
cancer
polyradiculoneuropathy
  • 214 views
  • 11 Jul, 2022
  • 3 locations
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives.

ejection fraction
filgrastim
mitoxantrone
granulocyte colony stimulating factor
colony stimulating factor
  • 60 views
  • 01 May, 2022
  • 1 location
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

study are: ALRN-6924 Cytarabine (for patients with leukemia only)

mercaptopurine
lymphoma
solid tumor
cancer
PCR test
  • 65 views
  • 01 Jul, 2022
  • 4 locations
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

: Venetoclax Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine

mercaptopurine
cyclophosphamide
lymphoid leukemia
etoposide
dexamethasone
  • 3 views
  • 01 Feb, 2022
  • 2 locations
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as

cyclophosphamide
measurable disease
neutrophil count
cancer
mantle cell lymphoma
  • 0 views
  • 09 Apr, 2022
  • 1 location
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

myeloid leukemia. This study involves the following: Venetoclax and decitabine (investigational combination) Cytarabine and idarubicin (per standard of care)

  • 0 views
  • 13 Mar, 2022
  • 1 location
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for

daunorubicin
consolidation therapy
cytarabine
fludarabine
busulfan
  • 0 views
  • 09 Aug, 2022
  • 1 location
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old

ejection fraction
daunorubicin
cancer
chronic myelomonocytic leukemia
cytarabine
  • 0 views
  • 23 May, 2022
  • 3 locations